• Ascentage Pharma Group International set 17 clinical updates for presentation at European Hematology Association Congress in Stockholm on June 11-14, 2026, with results to be shown in poster sessions on June 13.
• Disclosures center on its leukemia drug olverembatinib, including updated study readouts in second-line chronic-phase chronic myeloid leukemia and data in harder-to-treat patients previously resistant to other therapies.
• Program also includes updated results from POLARIS-1, a global registrational Phase 3 study evaluating olverembatinib with low-intensity chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
• Separate abstracts cover lisaftoclax in CLL/SLL, including analyses linking baseline patient characteristics to outcomes in a pivotal Phase 2 study, alongside an early-stage pediatric combination study of olverembatinib with lisaftoclax in relapsed or refractory Ph+ ALL.
• Set of presentations signals continued clinical momentum for two core assets, with emphasis on expansion into earlier-line settings and combination regimens that could support broader commercial positioning if later-stage results hold.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605122215PRIMZONEFULLFEED9719138) on May 13, 2026, and is solely responsible for the information contained therein.